Avelumab + N-803 + haNK™
Phase 2Terminated 0 views this week 0 watching💤 Quiet
Interest: 24/100
24
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Merkel Cell Carcinoma
Conditions
Merkel Cell Carcinoma
Trial Timeline
Feb 19, 2020 → Sep 19, 2022
NCT ID
NCT03853317About Avelumab + N-803 + haNK™
Avelumab + N-803 + haNK™ is a phase 2 stage product being developed by ImmunityBio for Merkel Cell Carcinoma. The current trial status is terminated. This product is registered under clinical trial identifier NCT03853317. Target conditions include Merkel Cell Carcinoma.
What happened to similar drugs?
0 of 1 similar drugs in Merkel Cell Carcinoma were approved
Approved (0) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
12
Activity
0
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03853317 | Phase 2 | Terminated |
Competing Products
20 competing products in Merkel Cell Carcinoma